On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

Here's why Eli Lilly is a no-brainer stock to buy on the ... position in developing an oral obesity drug. He noted that oral products are probably the best solution for many of the "potential ...

Probably the biggest objection to buying Lilly stock is its valuation. The big pharmaceutical company's shares trade at nearly 37.5 times forward earnings. Does this high multiple disqualify Lilly as ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Through an analysis of Eli Lilly, we can infer the following trends ... showcasing exceptional sales performance and strong demand for its products or services. Debt To Equity Ratio The debt ...